Updated: Jan 18
Thank you for visiting our news blog, where you will find the latest updates on Vesynta projects, products and publications, along with the most recent developments in the field of precision dosing.
Vesynta was founded in 2018 by Stefan Guldin, Alaric Taylor and Jugal Suthar following the development of a promising drug quantification platform by the AdReNa research group at University College London (UCL), funded by the Horizon 2020 initiative DIACHEMO. The concept presented as a tool for clinicians to determine blood drug levels following chemotherapy treatment of clinically challenging patients such as young children, infants and neonates. The company has since guided platform development towards point-of-care blood analysis for routine application in therapeutic drug monitoring (TDM). Vesynta continues to work closely with UCL on their current research and development projects.
Our activities revolve around moral, ethical and rational scientific innovation, for the advancement of care and health for all patients.
Vesynta's mission is to deliver bespoke treatment to every patient, regardless of their age, gender, ethnicity or health status.
What we do
We enable the precision dosing of life-saving medicines, advancing their safety and effectiveness. Our people aspire to improve health outcomes and experiences for patients, by reducing life-limiting side effects and fatalities associated with sub-optimal treatment.
How we do it
Vesynta's blood monitoring platform enables individualised drug analysis by the patient's bedside. Our innovations combine robotic automation, analytical software and machine learning, to provide clinicians with a universal solution to determine a patient's medicine exposure. This data-guided approach supports smarter clinical decisions and personalised dosing regimes tailored to the individual's pharmacology, ensuring the best possible treatment and care.
Why we do it
Conventional medical practice determines a patient’s drug dose based upon their body weight or body surface area. However, this approach is based on an average using generic models that are built from subjects that are mainly healthy Caucasian adult males.
Naturally, this does not fully consider the unique ability of an individual to process a drug, as this is dependent on the patient’s body shape, state of health and genetic predispositions amongst other factors including age, gender and ethnicity. By under-representing patient groups that sit within young, old, female, ethnic minority and obese/malnourished classifications, we run the risk of over-dosing or under-dosing the individual. The outcome is a frequent experience of side-effects and poorly treated conditions that reduce quality of life and prognosis.
Vesynta’s solution for direct assessment of “drug exposure” during the course of treatment for each patient can overcome sub-optimal dosing regimes of life-critical medicine and remains the primary method to truly personalise dosing. Crucially, our approach becomes more accurate over time due to continuous and deep learning from clinical data, allowing for dosing to adapt as a patient’s condition and health develops.
Thank you for reading. If you would like more information about what we do, please contact us at firstname.lastname@example.org